Bank of America
VVOS icon

Bank of America’s Vivos Therapeutics VVOS Stock Holding History

Bank of America’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-132
Closed -$267 – 6902
2025
Q4 		$267 Buy
132
+15
+13% +$37 ﹤0.01% 6654
2025
Q3 		$363 Sell
117
-20
-15% -$91 ﹤0.01% 7639
2025
Q2 		$433 Buy
137
+7
+5% +$18 ﹤0.01% 7698
2025
Q1 		$370 Buy
130
+10
+8% +$39 ﹤0.01% 7576
2024
Q4 		$515 Buy
120
+14
+13% +$47 ﹤0.01% 7404
2024
Q3 		$277 Buy
106
+3
+3% +$8 ﹤0.01% 7499
2024
Q2 		$229 Buy
103
+23
+29% +$56 ﹤0.01% 7531
2024
Q1 		$386 Buy
+80
New +$478 ﹤0.01% 7297
2023
Q1 		– Sell
-2
Closed -$18 – 8310
2022
Q4 		$18 Buy
+2
New +$29 ﹤0.01% 8003
2022
Q1 		– Sell
-1
Closed – – 8804
2021
Q4 		$0 Buy
+1
New +$81 ﹤0.01% 8674

Other funds holding VVOS

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Bank of America's VVOS Position: Q1 2026 in Review

Bank of America sold out of Vivos Therapeutics (VVOS) in Q1 2026, closing a stake of 132 shares — an estimated $267 sold.

Bank of America first reported a position in VVOS in Q4 2021 and held it in 10 quarters. The position peaked at $515 in Q4 2024. 24 funds tracked by Wall St. Rank hold VVOS as of Q1 2026.

  • Bank of America reported no remaining Vivos Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 132 Vivos Therapeutics shares in Q1 2026, an estimated $267.
  • Bank of America first reported a position in Vivos Therapeutics in Q4 2021 and held it in 10 quarters.
  • Bank of America's Vivos Therapeutics position peaked at $515 in Q4 2024.
  • 24 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.